Regeneron PharmaceuticalsREGN

01Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 48% and 39% of our total revenues for the six months ended June 30, 2026 and 2025, respectively The increase in our share of profits for the three and six months ended June 30, 2026, compared to the same periods in 2025, was driven by higher profits primarily associated with an increase in Dupixent net product sales We co-commercialize Dupixent in the United States and in certain countries outside the United States

02EYLEA HD was launched in 2023 and entered the highly competitive environment described above The FDA recently approved EYLEA HD for the treatment of RVO and for additional dosing regimens

03We have large-scale manufacturing operations in Rensselaer, New York and Limerick, Ireland We constructed a fill/finish facility in Rensselaer, New York that is currently undergoing process validation

04Our VelocImmune technology, other antibody generation technologies, and late-stage and earlier-stage clinical candidates face competition from many pharmaceutical and biotechnology companies Many of our products and product candidates may be used, if approved, in combination with a drug-delivery device, including a pre-filled syringe, patch pump, auto-injector, or other delivery system Product candidates in Phase 2 and Phase 3 clinical development include fianlimab, odronextamab, linvoseltamab, itepekimab, pozelimab + cemdisiran, and olatorepatide